Biosimilars Rheumatology Roundup: June 2025

The Top 5 Biosimilar Articles for the Week of May 27

May 31st 2024

By Cameron Santoro

Here are the top 5 biosimilar articles for the week of May 27, 2024.

Biosimilars Gastroenterology Roundup: May 2024

May 30th 2024

By Skylar Jeremias

May proved to be a big month for biosimilar research, particularly in the gastroenterology space, where new data on infliximab and adalimumab products from conferences and journals alike demonstrated positive clinical results showcasing the safety of these products as well as switching to them.

Managing Treatment Strategies for Osteoporosis Amid Evolving Biologic and Biosimilar Landscape

May 30th 2024

Jeffrey Curtis, MD, MS, MPH, provides expert perspective for navigating the evolving treatment landscape of osteoporosis and key considerations for biologic and biosimilar utilization.

FDA Approves First Eculizumab Biosimilar

May 29th 2024

By Skylar Jeremias

The FDA approved Bkemv (eculizumab-aeeb) as the first biosimilar to Soliris (eculizumab) for 2 rare diseases. It was also approved with interchangeability.

New Evidence Confirms Safe Biosimilar-to-Biosimilar Switching

May 28th 2024

By Skylar Jeremias

A literature review revealed new data demonstrating that biosimilar-to-biosimilar switching is safe and effective.

Eye on Pharma: Simlandi US Launch; Ranibizumab Partnership; Expanded Access for Adalimumab Biosimilars

May 27th 2024

By Skylar Jeremias

Alvotech and Teva have launched Simlandi in the US; Xbrane Biopharma and STADA Arzneimitel partner with Valorum Biologics to bring a ranibizumab biosimilar to the US; Boehringer Ingelheim and Celltrion take steps to expand access to their respective adalimumab biosimilars.

Insights From Cencora's Dr Lakesha Farmer: Innovative Biosimilar Adoption Strategies

May 26th 2024

By Skylar Jeremias

Lakesha Farmer, PharmD, MBA, from Cencora discusses innovative pricing and reimbursement models incentivizing biosimilar adoption and competitiveness, including dual pricing strategies and the Mark Cuban Cost Plus Program, while highlighting potential impacts on patient assistance programs.

High Clinical Remission, Treatment Persistence With Adalimumab Biosimilar in Pediatric IBD

May 25th 2024

By Deana Ferreri, PhD

A real-world study of the use of adalimumab biosimilars in pediatric inflammatory bowel disease (IBD) in Sicily found “high rates” of clinical remission and treatment persistence, and no unexpected safety concerns.

The Top 5 Biosimilar Articles for the Week of May 20

May 24th 2024

By Cameron Santoro

Here are the top 5 biosimilar articles for the week of May 20, 2024.

Posters Demonstrate Switching Safety Between Originator, Biosimilar Infliximab in IBD

May 23rd 2024

By Skylar Jeremias

Two posters from Digestive Disease Week found that switching patients with inflammatory bowel disease (IBD) from Remicade to an infliximab biosimilar did not impact clinical outcomes, with one study focusing on switches in pediatric patients and the other focusing on patients undergoing multiple switches.